Abstract. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been the focus as a potential anticancer drug, because it induces apoptosis in a wide variety of cancer cells but not in most normal human cell types. In this study, we showed that combination treatment with sub-toxic doses of antimycin A (AMA), an inhibitor of electron transport, plus TRAIL induced apoptosis in human renal cancer cells, but not in normal tubular kidney cells. Treatment of Caki cells with AMA upregulated the death receptor 5 (DR5) protein and downregulated c-FLIP and Bcl-2 proteins in a dose-dependent manner. AMA-induced decrease of c-FLIP L and c-FLIPs protein levels which were caused by increased protein instability, which was confirmed by the result showing that treatment with a protein biosynthesis inhibitor, CHX, accelerated degradation of c-FLIP L and c-FLIPs proteins caused by AMA treatment. We also found that AMA induced upregulation of DR5 and downregulation of Bcl-2 at the transcriptional level. Pretreatment with N-acetyl-l-cysteine (NAC) partly recovered the expression levels of c-FLIP L and c-FLIPs proteins were downregulated by the AMA treatment, suggesting that AMA appears to be partially dependent on the generation of ROS for downregulation of c-FLIP L and c-FLIPs. Collectively, this study demonstrates that AMA enhances TRAIL-induced apoptosis in human renal cancer cells by upregulation of DR5 as well as downregulation of c-FLIP and Bcl-2. Furthermore, this study shows that AMA markedly increases sensitivity to cisplatin in Caki human renal cancer cells.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is considered as a new potential anticancer drug.
TRAIL induces apoptosis in various types of cancer cells in vitro and in vivo, but has little or no toxicity against normal cells, which is supported by the presence of large numbers of decoy receptors on normal cells (1, 2) . Since TRAIL is a tumorselective and apoptosis-inducing cytokine, it is considered to be a promising new candidate for cancer prevention and treatment. However, recent studies have shown that some cancer cells are resistant to the apoptotic effects of TRAIL (3) (4) (5) . TRAIL-resistant cancer cells can be sensitized by chemotherapeutic drugs and biochemical inhibitors in vitro, indicating a possibility of combination therapy. Therefore, understanding the molecular mechanisms of TRAIL resistance and ways to sensitize these cells for apoptosis by TRAIL are important issues for effective cancer therapy.
Antimycin A (AMA) inhibits succinate oxidase and nicotinamide adenine dinucleotide (NADH) oxidase and also blocks mitochondrial electron transport by binding to complex III (6) . Inhibition of electron transport causes the collapse of the mitochondrial proton gradient across the mitochondrial inner membrane and the mitochondria membrane potential (MMP), thus allowing production of reactive oxygen species (ROS) as well as the release of proapoptotic molecules such as cytochrome c (7) (8) (9) (10) (11) . Although a large number of studies have shown antitumor activity of AMA, anticancer effects of the combination of AMA and TRAIL are not clear. This study was designed to evaluate the combination treatment with AMA and TRAIL and to delineate the underlying mechanism associated with observations in vitro demonstrated by synergistic effects between AMA and TRAIL in renal cancer cells.
Materials and methods

Cells and materials.
Caki cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Dulbecco's modified Eagle's medium (DMEM), containing 10% fetal bovine serum (FBS), 20 mM HEPES buffer and 100 µg/ml gentamicin was the culture medium used throughout the experiments. AMA and TRAIL was directly added to cell cultures at the indicated concentrations. Anti-Bcl-2, anti-procaspase-3, anti-PARP and anti-actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-c-FLIP antibody was purchased from Alexis Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2 
RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR).
RT-PCR analysis was done as previously reported (12) . The cDNA for DR5 and actin were amplified by PCR with specific primers. The sequences of the sense and antisense primers for DR5 were 5'-AAGACCCTTGTGCTCG TTGT-3' and 5'-GACACATTCGATGTCACTCCA-3' , respectively. PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide. For CHOP, the sense primer 5'-CAACTGCAGAGATGGCAGCTGA-3' and the antisense primer 5'-CTGATGCTCCCAATTGTTCAT-3' (corresponding to a 536-bp region of CHOP) were used. The sequences of the sense for c-FLIP L and c-FLIPs were 5'-CGGACTATAGAGTGCTG ATGG-3' and the antisense primers were 5'-GATTATCAGGCA GATTCCTAG-3' (c-FLIP L ) and 5'-AGATCAGGACAATGGG CATAG-3' (c-FLIPs), respectively. Statistical analysis. Three or more separate experiments were performed. Statistical analysis was done by paired Student's t-test or ANOVA. A p<0.05 was considered to have pronounced difference between experimental and control groups.
Results
AMA sensitizes renal cancer cells for TRAIL-mediated apoptosis.
In an attempt to search for novel strategies to overcome TRAIL resistance in cancer cells, we investigated the effect of combination treatment of AMA and TRAIL in human renal cancer cell line, Caki cells. Co-treatment of Caki cells with AMA and TRAIL resulted in a markedly increased in accumulation of sub-G1 phase cells, compared with Caki cells treated with AMA or TRAIL alone (Fig. 1A) . In addition, combination treatment of Caki cells with AMA and TRAIL led to the reduction of the protein levels of procaspase 3. The protein levels of c-FLIP L , c-FLIPs, Mcl-1 and Bcl-2 were remarkably reduced in response to combination of AMA plus TRAIL (Fig. 1B) . Next, we analyzed nuclear condensation, which is another hallmark of apoptosis. Combination treatment with AMA plus TRAIL induced the nuclear condensation in Caki cells. However, we failed to detect nuclear condensation in Caki cells treated with TRAIL or AMA alone (Fig. 1C) . Next, we investigated whether co-treatment with AMA and TRAIL affected TCMK-1 normal renal tubular epithelial cells. Interestingly, TCMK-1 cells were resistant to AMA or TRAIL alone, and cell morphology was not significantly affected by combination treatment with AMA and TRAIL (Fig. 1D ).
Combination treatment with AMA plus TRAIL induced apoptosis is mediated via caspase-dependent pathway. We next examined whether activation of caspase pathway plays a critical role in AMA plus TRAIL-induced apoptosis. As shown in Fig. 2A , AMA plus TRAIL-induced apoptosis was completely prevented by pretreatment with the general and potent inhibitor of caspases, z-VAD-fmk, as determined by FACS analysis. We also found that z-VAD-fmk prevented all these caspase-related events including cleavage of procaspase-3 and PARP (Fig. 2B) . These results suggest that combined treatment of AMA and TRAIL-induced apoptosis was mediated by caspase-dependent apoptosis pathways.
AMA downregulates c-FLIP and Bcl-2 protein expressions but upregulates DR5 and CHOP proteins expression.
To investigate the underlying mechanisms involved in combination treatment of AMA and TRAIL-induced apoptosis, we analyzed the expression levels of various apoptosis regulating proteins using western blot assay. While protein levels of c-FLIP L , c-FLIPs, and Bcl-2 were noticeably reduced in response to AMA treatment, the levels of death receptor 5 (DR5) and CHOP proteins were increased by AMA treatment (Fig. 3A) . Next, we examined whether AMA-mediation of c-FLIP L , c-FLIPs and Bcl-2 downregulation were controlled at the transcriptional level. RT-PCR analysis demonstrated that AMA decreased Bcl-2 mRNA levels in a dosedependent manner. In addition, we found that DR5 and CHOP mRNA levels were increased by AMA treatment (Fig. 3B ) in a dose dependent manner. However, c-FLIP L and c-FLIPs mRNA levels remained constant throughout the AMA treatment at different doses in Caki cells (Fig. 3B) . These results suggest the possibility that AMA-mediated degradation of c-FLIP L and c-FLIPs proteins might be regulated by post-transcriptional levels. To further clarify the underlying mechanisms of the decreased c-FLIP L and c-FLIPs protein levels in AMA-treated cells, we analyzed the protein stability test of c-FLIP L and c-FLIPs. Caki cells were treated with cycloheximide (CHX) and AMA at different doses. We found that the degradation of c-FLIP L and c-FLIPs protein were facilitated by AMA treatment (Fig. 3C) , which implies that AMA treatment caused reduction of c-FLIP protein stability. We also found that AMA-induced downregulations of c-FLIP L and c-FLIP S proteins were partly blocked by pretreatment of anti-oxidant N-acetyl-L-cysteine (NAC) (Fig. 3D) . These results suggest the possibility that AMA-stimulated downregulation of c-FLIP protein appears to be partly dependent on the generation of reactive oxygen species (ROS). (Fig. 4A) . Cleavage of PARP and procaspase 3 induced by combination treatment were also markedly inhibited by the overexpression of c-FLIP L and c-FLIP S (Fig. 4B) . These results suggest that c-FLIP L and c-FLIP S downregulations also contribute to AMA-facilitated TRAIL-induced apoptosis.
Downregulation of c-FLIP
AMA sensitizes renal cancer cells to cisplatin-mediated apoptosis.
We also investigated whether the sensitivity against chemotherapeutic agent, cisplatin, increases in Caki cells. As shown in Fig. 5A , pretreatment with AMA augmented the sensitivity to cisplatin. In addition, combination treatment of Caki cells with AMA and cisplatin led to a reduction of the protein level of procaspase 3 together with a concomitant cleavage of PARP, a substrate protein of caspases (Fig. 5B) .
Discussion
In this study, we demonstrated for the first time that combination treatment with AMA plus TRAIL on renal cancer cells synergistically induced apoptosis. AMA-induced upregulation of DR5 or AMA-mediated downregulation of Bcl-2 is controlled at the transcriptional level in a dose-dependent manner. In contrast, AMA-induced downregulation of c-FLIP L and c-FLIPs is caused by facilitating degradation of c-FLIP protein. In addition, we also found that production of ROS by AMA treatment seemed to partially take part in c-FLIP L and c-FLIPs downregulations.
Induction of DR5 expression is an important underlying mechanism for sensitization of TRAIL-mediated apoptosis (13) (14) (15) . In this study, we detected the induction of CHOP mRNA and DR5 mRNA expressions in AMA-treated Caki cells, indicating the possible involvement of DR5 modulation in AMA-induced sensitization of TRAIL-prompted apoptosis in these cells. However, several reports have shown that CHOP upregulates DR5 expression at the transcriptional level (4, 16) and we failed to detect that AMA-induced CHOP expression was related to DR5 upregulation (data not shown). Future studies will determine the mechanism of action of AMA treatment for upregulation of DR5 at the transcriptional level.
Several reagents such as compound C, rosiglitazone, LBH589 and silibinin can induce downregulation of c-FLIP and subsequent sensitization to TRAIL-induced apoptosis in different cancer cells (16) (17) (18) (19) . In this study, treatment with AMA induced downregulation of c-FLIP L and c-FLIPs and the enforced expression of c-FLIP L and c-FLIPs abrogated the induction of apoptosis by combination treatment with AMA and TRAIL. These results suggested a critical role of c-FLIP L and c-FLIPs downregulation in mediating the augmentation of TRAIL-induced apoptosis by AMA. It is generally recognized that c-FLIP L and c-FLIPs protein levels can be regulated by ubiquitin/proteasome mediated degradation (20, 21) or by their transcriptional control through the NF-κB or c-Fos pathway (22, 23) . In our study, AMA promotes ubiqutin/proteasome-mediated degradation of c-FLIP L and c-FLIPs, leading to downregulation of c-FLIP, but not by transcriptional control. Recently, several studies have shown that ROS downregulates c-FLIP levels and increases the sensitivity to apoptotic stimuli (24, 25) . Therefore, we investigated whether downregulation of c-FLIP L and c-FLIPs was actually mediated by ROS signaling pathway. In the presence of NAC, the decreased levels of c-FLIP L and c-FLIPs caused by AMA were partly restored. Taken together, AMA-stimulated TRAILinduced apoptosis appears to be dependent on the formation of ROS for downregulations of c-FLIP L and c-FLIPs.
In summary, we suggest that AMA may be a potentially important therapeutic approach for enhancing sensitivity to TRAIL via downregulations of proteins related to the inhibition of the apoptotic processes such as Bcl-2 and c-FLIP as well as upregulation of DR5 proteins. Additionally, this study showed that AMA markedly increases sensitivity to conventional cancer chemotherapeutic agent, cisplatin, in human renal cancer Caki cells. 
